Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after HCV cure with DAAs in patients with cirrhosis or high FIB-4

Posted on June 28, 2022 by Gastroenterology Journal
This entry was posted in News. Bookmark the permalink.